PROK

ProKidney Corp. Class A Ordinary Shares (PROK) | Rumor.io

ProKidney

PROK

Attention (50-day avg)0%

Attention rank (50-day avg)#2,914

Bullish sentiment (50-day avg)89%

Price to earnings ratio-3.08

Market capitalization642.7M

Earnings per share-0.55

Dividend yield (TTM)267.5%

Revenue (annual)893K

Net income (annual)-151.6M

Social

What share of all stock conversation is about PROK?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% new	0% 0	0% -0.01

May 28

ProKidney Corp. (PROK) has 94% of its float shorted, with 49.18% of the float shorted.
This high short interest could be a sign of market expectations for a potential price drop.
The company's float is approximately 39.1 million shares.

Generated by AI

Sentiment

Of the messages about PROK that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100%	100% +33.33	16.13% -63.67
Bearish	—	0%	0% -33.33	83.87% +63.67

Bullish· Oct 8

The chairman's $54 million investment in PROK at $2.40 per share is a bullish sign, especially considering the stock's potential for a buyout.
PROK's upcoming clinical results and earnings in the coming months are expected to drive price changes, with the market already buzzing about the stock's potential.
The stock's past performance, including a 50% gain and a successful squeeze, suggests it has the potential for significant price increases, with some analysts predicting a 1000% return.

Bearish· Jul 16

The author believes $PROK will drop below $1 due to a combination of factors, including a $200M offering and a low float and volume.
The company's low volume and float make it susceptible to significant price movements, which could lead to a further decline.
The author believes that the current price movement is a "pump and dump" scheme, and that the company's $200M offering will be used to unload shares on unsuspecting investors.

Generated by AI

Topics

Of the messages about PROK that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	89.55%
Analysts	—	—	0%	4.3%
Controversies	—	—	0%	0%
Earnings	—	—	0%	0%
Macro	—	—	0%	4.04%
Technical Analysis	—	—	0%	2.11%

Announcements· Jul 15

ProKidney Corp. ($PROK) has received FDA green light on the accelerated approval pathway for its lead therapy, rilparencel, for chronic kidney disease.
UBS reiterates buy rating on $PROK with a raised price target of $8 (from $4) due to the potential for accelerated approval and positive Phase 2 eGFR stabilization data.
The FDA has confirmed the eGFR slope as an acceptable surrogate endpoint in CKD + T2D, and ProKidney is expected to submit a BLA in Q2 2027 to support full approval.

Technical Analysis· Jul 10

The author is bearish on $PROK in the short to mid-term, citing fundamentals such as red EPS, no income, and funding cut by BofA.
Key technical levels for $PROK include $6.47, broken down with heavy volume, and $5.35, where a juicy iceberg trade is sitting.
The author notes that $PROK is building an uptrend on steady low volume, but is cautious and only bullish if the price action meets certain criteria.

Generated by AI

Community

Of the messages about PROK, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	100%	62.5%	29.56%
Newcomers	—	0%	37.5%	70.44%

Sep 12

The newcomer is looking at $PROK as a potential buy, breaking through key resistance, with a surge in trading volume suggesting growing institutional interest.
The focus is on setting up for a move higher with HVE candle, high ADR, and reclaiming 12/12 EMAs, with a price target of $4.23-$4.87 as it continues to trade in a lower descending wedge.
The newcomer is considering a long position in $PROK with an opening price of $3.10, stop-loss at $2.5, and expected first and second target price ranges of $3.7 and $4.2 respectively.

Generated by AI

News

ProKidney (PROK) Nears A Pivotal Kidney Therapy Verdict

19d agoYahoo Finance

ProKidney director Brian Pereira sells $1.07 million in shares

1mo agoInvesting.com

Prokidney Insider Sold Shares Worth $1,067,773, According to a Recent SEC Filing

1mo agoYahoo Finance

ProKidney: Do-Or-Die Phase 3 Meets A Dwindling Balance Sheet (Rating Downgrade) (PROK)

1mo agoSeeking Alpha

ProKidney (PROK) Gets a Buy from Guggenheim

Detailed price information for Prokidney Corp (PROK-Q) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

ProKidney earnings missed, revenue topped estimates

1mo agoInvesting.com

Also Discussed

Investors talking about PROK also mention

#	Name	Attention
1	Calidi Biotherapeutics, Inc.CLDI	0%0
2	Above Food Ingredients Inc.ABVE	0%new
3	KNW - Know Labs, Inc.	——
4	MODV - ModivCare Inc.	——
5	IO Biotech, Inc.IOBT	0%0
6	Vor Biopharma Inc.VOR	0%new
7	BSLK - Bolt Projects Holdings, Inc.	——
8	MiNK Therapeutics, Inc.INKT	0%new
9	Presidio Property Trust, Inc. Class A Common StockSQFT	0%new
10	PTL Limited Class A Ordinary SharesPTLE	0%new

ProKidney Corp. Class A Ordinary Shares

Healthcare
Biotechnology

ProKidney Corp. Class A Ordinary Shares represent equity in ProKidney, a clinical-stage biotechnology company focused on developing cell-based therapies for chronic kidney disease. The company’s work centers on proprietary autologous cell therapy platforms designed to support kidney function in patients with advanced kidney disease and diabetes. Its lead therapeutic program is directed at treating moderate to severe diabetic kidney disease and other chronic kidney conditions, placing ProKidney in the broader renal therapeutics sector. The company’s current business is concentrated on research, clinical development, and the advancement of its cell therapy candidates, making it a specialized participant in the biotechnology market. ProKidney Corp. is headquartered in Winston-Salem, North Carolina, and its Class A ordinary shares are one of the company’s publicly traded equity classes.

Website

Location

2000 Frontis Plaza Boulevard

Winston-Salem, NC, 27103

United States

Social

What share of all stock conversation is about PROK?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% new	0% 0	0% -0.01

May 28

ProKidney Corp. (PROK) has 94% of its float shorted, with 49.18% of the float shorted.
This high short interest could be a sign of market expectations for a potential price drop.
The company's float is approximately 39.1 million shares.

Generated by AI

Sentiment

Of the messages about PROK that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100%	100% +33.33	16.13% -63.67
Bearish	—	0%	0% -33.33	83.87% +63.67

Bullish· Oct 8

The chairman's $54 million investment in PROK at $2.40 per share is a bullish sign, especially considering the stock's potential for a buyout.
PROK's upcoming clinical results and earnings in the coming months are expected to drive price changes, with the market already buzzing about the stock's potential.
The stock's past performance, including a 50% gain and a successful squeeze, suggests it has the potential for significant price increases, with some analysts predicting a 1000% return.

Bearish· Jul 16

The author believes $PROK will drop below $1 due to a combination of factors, including a $200M offering and a low float and volume.
The company's low volume and float make it susceptible to significant price movements, which could lead to a further decline.
The author believes that the current price movement is a "pump and dump" scheme, and that the company's $200M offering will be used to unload shares on unsuspecting investors.

Generated by AI

Topics

Of the messages about PROK that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	89.55%
Analysts	—	—	0%	4.3%
Controversies	—	—	0%	0%
Earnings	—	—	0%	0%
Macro	—	—	0%	4.04%
Technical Analysis	—	—	0%	2.11%

Announcements· Jul 15

ProKidney Corp. ($PROK) has received FDA green light on the accelerated approval pathway for its lead therapy, rilparencel, for chronic kidney disease.
UBS reiterates buy rating on $PROK with a raised price target of $8 (from $4) due to the potential for accelerated approval and positive Phase 2 eGFR stabilization data.
The FDA has confirmed the eGFR slope as an acceptable surrogate endpoint in CKD + T2D, and ProKidney is expected to submit a BLA in Q2 2027 to support full approval.

Technical Analysis· Jul 10

The author is bearish on $PROK in the short to mid-term, citing fundamentals such as red EPS, no income, and funding cut by BofA.
Key technical levels for $PROK include $6.47, broken down with heavy volume, and $5.35, where a juicy iceberg trade is sitting.
The author notes that $PROK is building an uptrend on steady low volume, but is cautious and only bullish if the price action meets certain criteria.

Generated by AI

Community

Of the messages about PROK, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	100%	62.5%	29.56%
Newcomers	—	0%	37.5%	70.44%

Sep 12

The newcomer is looking at $PROK as a potential buy, breaking through key resistance, with a surge in trading volume suggesting growing institutional interest.
The focus is on setting up for a move higher with HVE candle, high ADR, and reclaiming 12/12 EMAs, with a price target of $4.23-$4.87 as it continues to trade in a lower descending wedge.
The newcomer is considering a long position in $PROK with an opening price of $3.10, stop-loss at $2.5, and expected first and second target price ranges of $3.7 and $4.2 respectively.

Generated by AI

ProKidney

Social

May 28

Bullish· Oct 8

Bearish· Jul 16

Announcements· Jul 15

Technical Analysis· Jul 10

Sep 12

ProKidney (PROK) Nears A Pivotal Kidney Therapy Verdict

ProKidney director Brian Pereira sells $1.07 million in shares

Prokidney Insider Sold Shares Worth $1,067,773, According to a Recent SEC Filing

ProKidney: Do-Or-Die Phase 3 Meets A Dwindling Balance Sheet (Rating Downgrade) (PROK)

ProKidney (PROK) Gets a Buy from Guggenheim

ProKidney earnings missed, revenue topped estimates

Also Discussed

ProKidney Corp. Class A Ordinary Shares

Company Information

Location

Social

May 28

Bullish· Oct 8

Bearish· Jul 16

Announcements· Jul 15

Technical Analysis· Jul 10

Sep 12

ProKidney (PROK) Nears A Pivotal Kidney Therapy Verdict

ProKidney director Brian Pereira sells $1.07 million in shares

Prokidney Insider Sold Shares Worth $1,067,773, According to a Recent SEC Filing

ProKidney: Do-Or-Die Phase 3 Meets A Dwindling Balance Sheet (Rating Downgrade) (PROK)

ProKidney (PROK) Gets a Buy from Guggenheim

ProKidney earnings missed, revenue topped estimates

Also Discussed